Drug Trial Radar · NCT05729373
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
Last checked: Nov 20, 2026Latest source record: Oct 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
434
Actual
Start
Mar 8, 2023
Primary completion
Sep 26, 2025
Study completion Sep 26, 2025
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- First posted
- Feb 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A clinical study that will meaure how well SEP-363856 works and how safe it is in adults with Generalized Anixety Disorder. This study will be accepting both male and female subjects between the ages of 18 years and 65 years old. The study will be held in Approximately 50 global study centers and approximately 15 additional centers for a separate Japan population. Participation in the study can be up to approximately 12 weeks.
Conditions
- Generalized Anxiety Disorder
Interventions
SEP-363856Drug
once daily tablet
PlaceboDrug
once daily tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) total score at EndpointTime frame: Week 8
Locations
83 sites in 8 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Huntsville, Alabama
IMA Clinical Research Phoenix
Phoenix, Arizona
ProScience Research Group
Culver City, California
Excell Research, Inc.
Oceanside, California
Anderson Clinical Research
Redlands, California
California Neuroscience Research, LLC
Sherman, California
Schuster Medical Research Institute
Sherman Oaks, California
Viking Pharmaceutical Trials Inc. dba Viking Clinical Research
Temecula, California
CenExel Collaborative Neuroscience Research
Torrance, California
Pacific Clinical Research Management Group
Upland, California
CNS Healthcare
Jacksonville, Florida
Combined Research Orlando
Orlando, Florida
K2 Medical Research, LLC
Tampa, Florida
CenExel iResearch Atlanta
Atlanta, Georgia
Advanced Discovery Research LLC
Atlanta, Georgia
NeuroTrials Research, Inc.
Atlanta, Georgia
CenExel iResearch Savannah
Savannah, Georgia
Uptown Research Institute, LLC
Chicago, Illinois
American Medical Research, Inc.
Warrenville, Illinois
Copley Clinical
Boston, Massachusetts
Boston Clinical Trials
Boston, Massachusetts
Adams Clinical
Watertown, Massachusetts
Midwest Research Group
Saint Charles, Missouri
Center for Emotional Fitness Site
Cherry Hill, New Jersey
CenExel Hassman Research Institute
Marlton, New Jersey
Social Psychiatry Research Institute
Brooklyn, New York
Neurobehavioral Research, Inc.
Cedarhurst, New York
Bioscience Research, LLC
Mount Kisco, New York
Berman Clinical
New York, New York
Manhattan Behavioral Medicine
New York, New York
The Medical Research Network, L.L.C
New York, New York
Neuro-Behavioral Clinical Research, Inc.
North Canton, Ohio
Sooner Clinical Research
Oklahoma City, Oklahoma
Paradigm Research Professionals, LLP
Oklahoma City, Oklahoma
Lehigh Center for Clinical Research, LLC
Allentown, Pennsylvania
Psychiatry and Psychotherapy Partners Austin
Austin, Texas
FutureSearch Trials of Dallas, LP
Dallas, Texas
Cedar Clinical Research, Inc.
Draper, Utah
Medical Center Medconsult Pleven OOD
Pleven, Bulgaria
MHC - Sofia, EOOD
Sofia, Bulgaria
Showing 40 of 83 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.